Volume : 09, Issue : 12, December – 2022
Title:
15.NOSE TO BRAIN DRUG DELIVERY SYSTEM
Authors :
Ms. Samiksha Sunil Jawarkar, Dr.S.D. Pande
Abstract :
Nose-to-Brain Drug Delivery System is an approach to deliver a drug directly in brain through the nose. Intranasal Drug delivery is very beneficial as it avoids first pass mechanism and can achieve greater concentration of drugs in Central Nervous System (CNS) at very low dose. Delivery of a drug through nasal route has been potentially explored as an alternative route for the administration of vaccines and biomolecules. Nose-to-Brain drug delivery system is most widely used for the treatment of Neurological disease such as Alzheimer’s Disease, Parkinson’s Disease, etc. Such Disease affecting CNS and the most difficult to cure due to the presence of Blood Brain Barrier (BBB) which refers as the highly selective semi-permeable border of the epithelium cells surrounded by astrocyte foot processes. The Main Objective of this review report is to study some essential characteristics and their possible obstacles related to Nose-to-Brain Drug Delivery System which includes anatomy and physiology of Nose-to-Brain drug delivery system and also transport of drugs in nose-to-brain via Olfactory Nerve and Trigeminal Nerve Pathways by passing BBB.
Keywords: Nose-to-Brain, Intranasal Drug Delivery, Blood Brain Barrier, Olfactory Nerve Pathway, Trigeminal Nerve Pathway.
Cite This Article:
Please cite this article in press Samiksha Sunil Jawarkar et al, Nose To Brain Drug Delivery System.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
1. Hickey A.J., Pharmaceutical Inhalation Aerosol Technology, 2nd ed Marcel Dekker, Inc: NewYork, 2004;105:177-178. DOI: 10.1016/j.jconrel.2005.01.019.
2. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul. 2012;29(2):103-14. DOI: 10.3109/02652048.2011.630106.
3. Jadhav KR, Gambhire MN, Shaikh IM, et al. Nasal drug delivery system- factors affecting and applications. Curr Drug Ther 2007;2(1):27-38. DOI: 10.2174/157488507779422374.
4. Davis SS, Biomedical applications of nanotechnology- Implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15(6):217-24. DOI: 10.1016/S0167-7799(97)01036-6.
5. Mitthal D, Ali A, Shadab MD, Baboota S, Sahni JK and Ali J: Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv.2014;21(2):75-86. DOI: 10.3109/10717544.2013.838713.
6. Singhkumar Arun. Nasal Cavity: A promising transmucosal platform for drug delivery and research approach from nasal to brain targeting. Journal of Drug Delivery and Therapeutics. 2012;2(3):22-33. DOI:10.22270/jddt.v2i3.163.
7. Chhajed S.; Sangle S.; and Barhate S. Advantageous Nasal drug delivery system; A review. International journal of pharmaceutical science and research. 2011;2(6):1322-1336. DOI:10.13040/IJPSR.0975-8232.
8. Zaheer A.; Sachin., Swamy. Mucoadhesive Polymers: Drug Carriers for Improved Nasal Drug Delivery. Indian Journal of Novel Drug Delivery. Jan-Mar,2012;4(1):2-16
9. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379(1):146-57. DOI: 10.1016/j.ijpharm.2009.06.019.
10. Davis SS, Biomedical applications of nanotechnology- Implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15(6):217-24. DOI: 10.1016/S0167-7799(97)01036-6.
11. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. DOI: 10.1016/S1474-4422(10)70223-4.
12. Illum L. Nasal Clearance in the health and disease. J Aerosol Med 2006;19(1):92-9. DOI: 10.1089/jam.2006.19.92.
13. Bahadur S and Pathak K: Physiochemical and Physiological Considerations for efficient Nose-to-Brain Targeting. Expert Opinion on Drug Delivery 2012; 9(1):19-31. DOI: 10.1517/17425247.2012.636801.
14. Chen, Y.; Liu, L. Modern Methods for Delivery of Drugs across the Blood-Brain Barrier. Adv. Drug Deliv. Rev.2012,64(7),640-665. DOI: 10.1016/j.addr.2011.11.010.
15. Hawkins, B.T.; Egleton, R.D. Pathophysiology of the Blood-Brain Barrier: Animal Models and Methods. In Current Topics in Development Biology
; Academic Press: Cambridge, MA, USA, 2007; Volume 80, pp. 277-309. DOI: 10.1016/S0070-2153(07)80007-X.
16. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of Drugs across the Blood-Brain Barrier by Nanoparticles. J. Control. Release. 2012;161(2):264-273. DOI: 10.1016/j.jconrel.2011.08.017.
17. Pardridge, W.M. Drug Transport across the Blood-Blood Barrier. J.Cereb. Blood Flow Metab. 2012;32(11):1959-1972. DOI: 10.1038/jcbfm.2012.126.
18. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5(6):514-16. DOI: 10.1038/nn849.
19. Oberdorster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhaled Toxical 2004;16(6-7):437-45. DOI: 10.1080/08958370490439597.
20. Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanism and experimental considerations. J. Pharm Sci 2010;99(4):1654-73. DOI: 10.1002/jps.21924.
21. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481-96. DOI: 10.1016/j.neuroscience.2004.05.029.
22. Ibrahim A.; Alsarra A.Y.; Hamed., Fars K.A.; and Gamal M.; Maghraby E. Vesicular systems for Intranasal Drug Delivery, K.K. Jain (ed.), Drug Delivery to the Central Nervous System, Neuromethods 45. DOI: 10.1007/978-1-60761-529-3-8.
23. Craft S, Baker LD, Montine TJ, inoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, et al. (2012) Intranasal Insulin therapy for Alzheimer’s Disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38. DOI: 10.1001/archneurol.2011.233.
24. Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, et al. (2017) Effects of regular and long acting insulin on cognition and Alzheimer’s Disease biomarkers: a pilot clinical trial. J Alzheimer’s Dis 2017;57(4):1325-1334. DOI: 10.3233/JAD-161256.
25. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014;9:795-811. DOI: 10.2147/IJN.S52236.
26. Haque S, Md S, Alam MI, Sahni JK, Ali J, Baboota S. Nanostructure-based drug delivery systems for brain targeting. Drug Delivery Ind Pharm. 2012;38(4):387-411. DOI: 10.3109/03639045.2011.608191.
27. Rogovina LZ, Vasilev VG, Braudo EE. Definition of the concept of the polymer gel. Polym. Sci. Series C 2008;50:85-92. DOI: 10.1134/S1811238208010050.
28. Sarada K, Firoz S, Padmini K. In-situ gelling system: a rieview. Int J Curr Pharma Rev Res 2014;15(4):76-90.
29. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4): 329-344. DOI:10.1056/NEJMra0909142.
30. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208-245. DOI:10.1016/j.jalz.2013.02.003.
31. Hardy J, Selkoe DJ. The Amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356. DOI: 10.1126/science.1072994.
32. Danielyan L, von Ameln-Mayerhofer A, Bernhard F, et al. Therapeutic Efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinsons Disease. Rejuvenation Res 2011;14(1):3-16. DOI: 10.1089/rej.2010.1130.
33. Arumgam K., subramaniyam, G.S.,Mallayasamy, S.R, Averineni, R.K., Reddy, M.S,Udupa, N.(2008) A study of Rivastigmine liposomes for delivery into Brain through intra nasal route. Actapharm2008;58(3):287-297. DOI: 10.2478/v10007-008-0014-3.
34. Pakalnis A, Kring D, Paolichi J. Parenteral satisfaction with Sumatriptan Nasal spray in childhood migraine. J.Child Neurol, 2003;18(11):772-775. DOI: 10.1177/08830738030180110401.
35. Tiwari NG and Bajaj AN. formulation development of eucalyptuss oil microemulsion for intranasal delivery. Indian J Pharm Sci, 2007;69(5):731-733. DOI: 10.4103/0250-474X.38498.
36. Shende AJ, Patil RR and Devarajan PV, Microemulsion of lomotrigone for nasal delivery, Ind.J.Pharm. Sci.,2007;69(5):721-722. DOI:10.4103/0250-474X.38492.
37. Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting. J. Pharm. Sci.2006;95(3):570-80. DOI: 10.1002/jps.20480.
38. Kwatikar PS, kulkarni NP, yadav SP and sakarkarDM,formulation and evaluation of an anti-epileptic drug loaded microemulsion for nose to brain delivery, asian J. Pharmaceutics, april-june, 2009;3. DOI:10.22377/ajp.v3i2.256.
39. Pardridge W.M., Blood-Brain Barrier drug targeting: the future of brain drug development. Molecular interventions, 2003;3(2):90-105. DOI: 10.1124/mi.3.2.90.
40. Gladstone JP, Gawel M. Newer formulations of the Triptans: advances in migraine treatment. Drugs 2003;63(21):2285-2305. DOI: 10.2165/00003495-200363210-00002.
41. Zhang Q, Jiang X, Jiang W, Lu W, Su L and Shi 2, Preparation of Nimodipine loaded micro emulsion for intranasal delivery & evaluation on the targeting efficiency to the Brain. Inter.J.Pharmaceut. 2004;275(1-2):85-96. DOI: 10.1016/j.ijpharm.2004.01.039.
42. Han lk, Kim my, byun HM, Hwang T S, Kim JM, Hwang KW, Park T G, Jung W W , Chun T, JE\eona GJ, Oh Yk: Enhanced Brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. Jmol Med (Berl), 2007;85(1):75-83. DOI: 10.1007/S00109-006-0114-9.
43. Sau L. Lee, Lawrence X.Yu, Bring Cai, Gibbs R. Johnsons, Amy S. Rosenberg, Barry W. Chwrney, Wei Guo, Andre S. Raw. AAPS Journal, 2011;13(1):14-19.
44. Graff LC, Pollock GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94(6):1187-1195. DOI: 10.1002/jps.20318.
2. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul. 2012;29(2):103-14. DOI: 10.3109/02652048.2011.630106.
3. Jadhav KR, Gambhire MN, Shaikh IM, et al. Nasal drug delivery system- factors affecting and applications. Curr Drug Ther 2007;2(1):27-38. DOI: 10.2174/157488507779422374.
4. Davis SS, Biomedical applications of nanotechnology- Implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15(6):217-24. DOI: 10.1016/S0167-7799(97)01036-6.
5. Mitthal D, Ali A, Shadab MD, Baboota S, Sahni JK and Ali J: Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv.2014;21(2):75-86. DOI: 10.3109/10717544.2013.838713.
6. Singhkumar Arun. Nasal Cavity: A promising transmucosal platform for drug delivery and research approach from nasal to brain targeting. Journal of Drug Delivery and Therapeutics. 2012;2(3):22-33. DOI:10.22270/jddt.v2i3.163.
7. Chhajed S.; Sangle S.; and Barhate S. Advantageous Nasal drug delivery system; A review. International journal of pharmaceutical science and research. 2011;2(6):1322-1336. DOI:10.13040/IJPSR.0975-8232.
8. Zaheer A.; Sachin., Swamy. Mucoadhesive Polymers: Drug Carriers for Improved Nasal Drug Delivery. Indian Journal of Novel Drug Delivery. Jan-Mar,2012;4(1):2-16
9. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379(1):146-57. DOI: 10.1016/j.ijpharm.2009.06.019.
10. Davis SS, Biomedical applications of nanotechnology- Implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15(6):217-24. DOI: 10.1016/S0167-7799(97)01036-6.
11. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. DOI: 10.1016/S1474-4422(10)70223-4.
12. Illum L. Nasal Clearance in the health and disease. J Aerosol Med 2006;19(1):92-9. DOI: 10.1089/jam.2006.19.92.
13. Bahadur S and Pathak K: Physiochemical and Physiological Considerations for efficient Nose-to-Brain Targeting. Expert Opinion on Drug Delivery 2012; 9(1):19-31. DOI: 10.1517/17425247.2012.636801.
14. Chen, Y.; Liu, L. Modern Methods for Delivery of Drugs across the Blood-Brain Barrier. Adv. Drug Deliv. Rev.2012,64(7),640-665. DOI: 10.1016/j.addr.2011.11.010.
15. Hawkins, B.T.; Egleton, R.D. Pathophysiology of the Blood-Brain Barrier: Animal Models and Methods. In Current Topics in Development Biology
; Academic Press: Cambridge, MA, USA, 2007; Volume 80, pp. 277-309. DOI: 10.1016/S0070-2153(07)80007-X.
16. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of Drugs across the Blood-Brain Barrier by Nanoparticles. J. Control. Release. 2012;161(2):264-273. DOI: 10.1016/j.jconrel.2011.08.017.
17. Pardridge, W.M. Drug Transport across the Blood-Blood Barrier. J.Cereb. Blood Flow Metab. 2012;32(11):1959-1972. DOI: 10.1038/jcbfm.2012.126.
18. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5(6):514-16. DOI: 10.1038/nn849.
19. Oberdorster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhaled Toxical 2004;16(6-7):437-45. DOI: 10.1080/08958370490439597.
20. Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanism and experimental considerations. J. Pharm Sci 2010;99(4):1654-73. DOI: 10.1002/jps.21924.
21. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481-96. DOI: 10.1016/j.neuroscience.2004.05.029.
22. Ibrahim A.; Alsarra A.Y.; Hamed., Fars K.A.; and Gamal M.; Maghraby E. Vesicular systems for Intranasal Drug Delivery, K.K. Jain (ed.), Drug Delivery to the Central Nervous System, Neuromethods 45. DOI: 10.1007/978-1-60761-529-3-8.
23. Craft S, Baker LD, Montine TJ, inoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, et al. (2012) Intranasal Insulin therapy for Alzheimer’s Disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38. DOI: 10.1001/archneurol.2011.233.
24. Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, et al. (2017) Effects of regular and long acting insulin on cognition and Alzheimer’s Disease biomarkers: a pilot clinical trial. J Alzheimer’s Dis 2017;57(4):1325-1334. DOI: 10.3233/JAD-161256.
25. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014;9:795-811. DOI: 10.2147/IJN.S52236.
26. Haque S, Md S, Alam MI, Sahni JK, Ali J, Baboota S. Nanostructure-based drug delivery systems for brain targeting. Drug Delivery Ind Pharm. 2012;38(4):387-411. DOI: 10.3109/03639045.2011.608191.
27. Rogovina LZ, Vasilev VG, Braudo EE. Definition of the concept of the polymer gel. Polym. Sci. Series C 2008;50:85-92. DOI: 10.1134/S1811238208010050.
28. Sarada K, Firoz S, Padmini K. In-situ gelling system: a rieview. Int J Curr Pharma Rev Res 2014;15(4):76-90.
29. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4): 329-344. DOI:10.1056/NEJMra0909142.
30. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208-245. DOI:10.1016/j.jalz.2013.02.003.
31. Hardy J, Selkoe DJ. The Amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356. DOI: 10.1126/science.1072994.
32. Danielyan L, von Ameln-Mayerhofer A, Bernhard F, et al. Therapeutic Efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinsons Disease. Rejuvenation Res 2011;14(1):3-16. DOI: 10.1089/rej.2010.1130.
33. Arumgam K., subramaniyam, G.S.,Mallayasamy, S.R, Averineni, R.K., Reddy, M.S,Udupa, N.(2008) A study of Rivastigmine liposomes for delivery into Brain through intra nasal route. Actapharm2008;58(3):287-297. DOI: 10.2478/v10007-008-0014-3.
34. Pakalnis A, Kring D, Paolichi J. Parenteral satisfaction with Sumatriptan Nasal spray in childhood migraine. J.Child Neurol, 2003;18(11):772-775. DOI: 10.1177/08830738030180110401.
35. Tiwari NG and Bajaj AN. formulation development of eucalyptuss oil microemulsion for intranasal delivery. Indian J Pharm Sci, 2007;69(5):731-733. DOI: 10.4103/0250-474X.38498.
36. Shende AJ, Patil RR and Devarajan PV, Microemulsion of lomotrigone for nasal delivery, Ind.J.Pharm. Sci.,2007;69(5):721-722. DOI:10.4103/0250-474X.38492.
37. Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting. J. Pharm. Sci.2006;95(3):570-80. DOI: 10.1002/jps.20480.
38. Kwatikar PS, kulkarni NP, yadav SP and sakarkarDM,formulation and evaluation of an anti-epileptic drug loaded microemulsion for nose to brain delivery, asian J. Pharmaceutics, april-june, 2009;3. DOI:10.22377/ajp.v3i2.256.
39. Pardridge W.M., Blood-Brain Barrier drug targeting: the future of brain drug development. Molecular interventions, 2003;3(2):90-105. DOI: 10.1124/mi.3.2.90.
40. Gladstone JP, Gawel M. Newer formulations of the Triptans: advances in migraine treatment. Drugs 2003;63(21):2285-2305. DOI: 10.2165/00003495-200363210-00002.
41. Zhang Q, Jiang X, Jiang W, Lu W, Su L and Shi 2, Preparation of Nimodipine loaded micro emulsion for intranasal delivery & evaluation on the targeting efficiency to the Brain. Inter.J.Pharmaceut. 2004;275(1-2):85-96. DOI: 10.1016/j.ijpharm.2004.01.039.
42. Han lk, Kim my, byun HM, Hwang T S, Kim JM, Hwang KW, Park T G, Jung W W , Chun T, JE\eona GJ, Oh Yk: Enhanced Brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. Jmol Med (Berl), 2007;85(1):75-83. DOI: 10.1007/S00109-006-0114-9.
43. Sau L. Lee, Lawrence X.Yu, Bring Cai, Gibbs R. Johnsons, Amy S. Rosenberg, Barry W. Chwrney, Wei Guo, Andre S. Raw. AAPS Journal, 2011;13(1):14-19.
44. Graff LC, Pollock GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94(6):1187-1195. DOI: 10.1002/jps.20318.